Cargando…
Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy
OBJECTIVE: To evaluate the efficiency of resources allocation and sustainability of the use of netupitant+palonosetron (NEPA) for chemotherapy-induced nausea and vomiting (CINV) prophylaxis assuming the Italian National Health Service (NHS) perspective. A published Markov model was adapted to assess...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642784/ https://www.ncbi.nlm.nih.gov/pubmed/28765126 http://dx.doi.org/10.1136/bmjopen-2016-015645 |
_version_ | 1783271427670016000 |
---|---|
author | Restelli, Umberto Saibene, Gabriella Nardulli, Patrizia Di Turi, Roberta Bonizzoni, Erminio Scolari, Francesca Perrone, Tania Croce, Davide Celio, Luigi |
author_facet | Restelli, Umberto Saibene, Gabriella Nardulli, Patrizia Di Turi, Roberta Bonizzoni, Erminio Scolari, Francesca Perrone, Tania Croce, Davide Celio, Luigi |
author_sort | Restelli, Umberto |
collection | PubMed |
description | OBJECTIVE: To evaluate the efficiency of resources allocation and sustainability of the use of netupitant+palonosetron (NEPA) for chemotherapy-induced nausea and vomiting (CINV) prophylaxis assuming the Italian National Health Service (NHS) perspective. A published Markov model was adapted to assess the incremental cost-utility ratio of NEPA compared with aprepitant (APR) + palonosetron (PALO), fosaprepitant (fAPR) + PALO, APR + ondansetron (ONDA), fAPR + ONDA in patients receiving a highly emetogenic chemotherapy (HEC) and with APR + PALO and fAPR + PALO in patients receiving a moderately emetogenic chemotherapy (MEC). SETTING: Oncology hospital department in Italy. METHODS: A Markov model was used to determine the impact of NEPA on the budget of the Italian NHS on a 5-day time horizon, corresponding to the acute and delayed CINV prophylaxis phases. Direct medical costs considered were related to antiemetic drugs, adverse events management, CINV episodes management. Clinical and quality of life data referred to previously published works. The budget impact analysis considered the aforementioned therapies plus PALO alone (for HEC and MEC) on a 5-year time horizon, comparing two scenarios: one considering the use of NEPA and one not considering its use. PRIMARY AND SECONDARY OUTCOME MEASURES: Incremental cost per quality adjusted life year (QALY) and differential economic impact for the Italian NHS between the two scenarios considered. RESULTS: NEPA is more effective and less expensive (dominant) compared with APR + PALO (for HEC and MEC), fAPR + PALO (for HEC and MEC), APR + ONDA (for HEC), fAPR + ONDA (for HEC). The use of NEPA would lead to a 5-year cost decrease of €63.7 million (€42.7 million for HEC and €20.9 million for MEC). CONCLUSIONS: NEPA allows an efficient allocation of resources for the Italian NHS and it is sustainable, leading to a cost decrease compared with a scenario which does not consider its use. |
format | Online Article Text |
id | pubmed-5642784 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-56427842017-10-25 Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy Restelli, Umberto Saibene, Gabriella Nardulli, Patrizia Di Turi, Roberta Bonizzoni, Erminio Scolari, Francesca Perrone, Tania Croce, Davide Celio, Luigi BMJ Open Health Economics OBJECTIVE: To evaluate the efficiency of resources allocation and sustainability of the use of netupitant+palonosetron (NEPA) for chemotherapy-induced nausea and vomiting (CINV) prophylaxis assuming the Italian National Health Service (NHS) perspective. A published Markov model was adapted to assess the incremental cost-utility ratio of NEPA compared with aprepitant (APR) + palonosetron (PALO), fosaprepitant (fAPR) + PALO, APR + ondansetron (ONDA), fAPR + ONDA in patients receiving a highly emetogenic chemotherapy (HEC) and with APR + PALO and fAPR + PALO in patients receiving a moderately emetogenic chemotherapy (MEC). SETTING: Oncology hospital department in Italy. METHODS: A Markov model was used to determine the impact of NEPA on the budget of the Italian NHS on a 5-day time horizon, corresponding to the acute and delayed CINV prophylaxis phases. Direct medical costs considered were related to antiemetic drugs, adverse events management, CINV episodes management. Clinical and quality of life data referred to previously published works. The budget impact analysis considered the aforementioned therapies plus PALO alone (for HEC and MEC) on a 5-year time horizon, comparing two scenarios: one considering the use of NEPA and one not considering its use. PRIMARY AND SECONDARY OUTCOME MEASURES: Incremental cost per quality adjusted life year (QALY) and differential economic impact for the Italian NHS between the two scenarios considered. RESULTS: NEPA is more effective and less expensive (dominant) compared with APR + PALO (for HEC and MEC), fAPR + PALO (for HEC and MEC), APR + ONDA (for HEC), fAPR + ONDA (for HEC). The use of NEPA would lead to a 5-year cost decrease of €63.7 million (€42.7 million for HEC and €20.9 million for MEC). CONCLUSIONS: NEPA allows an efficient allocation of resources for the Italian NHS and it is sustainable, leading to a cost decrease compared with a scenario which does not consider its use. BMJ Publishing Group 2017-08-01 /pmc/articles/PMC5642784/ /pubmed/28765126 http://dx.doi.org/10.1136/bmjopen-2016-015645 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Health Economics Restelli, Umberto Saibene, Gabriella Nardulli, Patrizia Di Turi, Roberta Bonizzoni, Erminio Scolari, Francesca Perrone, Tania Croce, Davide Celio, Luigi Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy |
title | Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy |
title_full | Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy |
title_fullStr | Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy |
title_full_unstemmed | Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy |
title_short | Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy |
title_sort | cost-utility and budget impact analyses of the use of nepa for chemotherapy-induced nausea and vomiting prophylaxis in italy |
topic | Health Economics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642784/ https://www.ncbi.nlm.nih.gov/pubmed/28765126 http://dx.doi.org/10.1136/bmjopen-2016-015645 |
work_keys_str_mv | AT restelliumberto costutilityandbudgetimpactanalysesoftheuseofnepaforchemotherapyinducednauseaandvomitingprophylaxisinitaly AT saibenegabriella costutilityandbudgetimpactanalysesoftheuseofnepaforchemotherapyinducednauseaandvomitingprophylaxisinitaly AT nardullipatrizia costutilityandbudgetimpactanalysesoftheuseofnepaforchemotherapyinducednauseaandvomitingprophylaxisinitaly AT dituriroberta costutilityandbudgetimpactanalysesoftheuseofnepaforchemotherapyinducednauseaandvomitingprophylaxisinitaly AT bonizzonierminio costutilityandbudgetimpactanalysesoftheuseofnepaforchemotherapyinducednauseaandvomitingprophylaxisinitaly AT scolarifrancesca costutilityandbudgetimpactanalysesoftheuseofnepaforchemotherapyinducednauseaandvomitingprophylaxisinitaly AT perronetania costutilityandbudgetimpactanalysesoftheuseofnepaforchemotherapyinducednauseaandvomitingprophylaxisinitaly AT crocedavide costutilityandbudgetimpactanalysesoftheuseofnepaforchemotherapyinducednauseaandvomitingprophylaxisinitaly AT celioluigi costutilityandbudgetimpactanalysesoftheuseofnepaforchemotherapyinducednauseaandvomitingprophylaxisinitaly |